- Home
- OLMA vs RIGL Comparison
OLMA vs RIGL Comparison
Compare OLMA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- RIGL
- Stock Information
- Founded
- OLMA 2006
- RIGL 1996
- Country
- OLMA United States
- RIGL United States
- Employees
- OLMA N/A
- RIGL N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- RIGL Health Care
- Exchange
- OLMA Nasdaq
- RIGL Nasdaq
- Market Cap
- OLMA 289.0M
- RIGL 335.5M
- IPO Year
- OLMA 2020
- RIGL 2000
- Fundamental
- Price
- OLMA $5.28
- RIGL $19.20
- Analyst Decision
- OLMA Strong Buy
- RIGL Buy
- Analyst Count
- OLMA 4
- RIGL 5
- Target Price
- OLMA $24.50
- RIGL $36.40
- AVG Volume (30 Days)
- OLMA 688.0K
- RIGL 242.8K
- Earning Date
- OLMA 05-13-2025
- RIGL 05-06-2025
- Dividend Yield
- OLMA N/A
- RIGL N/A
- EPS Growth
- OLMA N/A
- RIGL N/A
- EPS
- OLMA N/A
- RIGL 2.08
- Revenue
- OLMA N/A
- RIGL $203,077,000.00
- Revenue This Year
- OLMA N/A
- RIGL $16.75
- Revenue Next Year
- OLMA N/A
- RIGL $13.74
- P/E Ratio
- OLMA N/A
- RIGL $9.21
- Revenue Growth
- OLMA N/A
- RIGL 70.16
- 52 Week Low
- OLMA $2.86
- RIGL $7.48
- 52 Week High
- OLMA $16.62
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- OLMA 60.00
- RIGL 50.40
- Support Level
- OLMA $4.80
- RIGL $18.32
- Resistance Level
- OLMA $5.61
- RIGL $19.91
- Average True Range (ATR)
- OLMA 0.38
- RIGL 1.09
- MACD
- OLMA 0.02
- RIGL -0.04
- Stochastic Oscillator
- OLMA 78.71
- RIGL 42.12
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.